---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009642"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:59.906946+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.
- Canvuparatide (HP): 1-year follow-up data from Phase 2 in Q2 2026; Phase 3 start on track for Q3 2026.
- MBX 4291 (obesity, GLP-1/GIP prodrug): 12-week Phase 1 data expected Q4 2026; potential once-monthly dosing.
- Two additional obesity candidates to be nominated in Q2 and Q3 2026: amycretin prodrug and GLP-1/GIP/GCGR triple agonist.
- Imapextide (PBH): Phase 2a data in Q2 2026; once-weekly dosing preferred in patient surveys.

## SEC filing metadata
- accession: 0001193125-26-009642
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000119312526009642/0001193125-26-009642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000119312526009642/mbx-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009642
- JSON: https://secwatch.observer/filing/0001193125-26-009642.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.